Positive Results From Theratechnologies’ Targeted Oncology Technology Presented On-Line at ASCO

NEXT STORY
Cue Biopharma Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, CUE-101, in Treatment of HPV-driven Cancers
PREV STORY
Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)

author_avatar
NASDAQ Market News

Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma

author_avatar
NASDAQ Market News

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress

RX-3117 showed Preliminary Efficacy in Pancreatic Cancer Patients for Whom Three or More Prior ...

author_avatar
NASDAQ Market News